Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
暂无分享,去创建一个
T. Ørntoft | K. Zieger | M. Borre | L. Dyrskjøt | T. Reinert | O. Gruselle | T. Coche | T. Kissow Lildal
[1] Carsten Wiuf,et al. Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers , 2011, Clinical Cancer Research.
[2] D. Jäger,et al. Protein expression of cancer testis antigens predicts tumor recurrence and treatment response to imatinib in gastrointestinal stromal tumors , 2011, International journal of cancer.
[3] M. Zago,et al. BCR–ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients , 2011, Oncogene.
[4] R. Vessella,et al. Expression of cancer/testis antigens in prostate cancer is associated with disease progression , 2010, The Prostate.
[5] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[6] Yao-Tseng Chen,et al. Cancer/testis (CT) antigens: Potential targets for immunotherapy , 2009, Cancer science.
[7] L. Lacombe,et al. High frequency of MAGE‐A4 and MAGE‐A9 expression in high‐risk bladder cancer , 2009, International journal of cancer.
[8] G. Schuler,et al. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells. , 2009, Cancer research.
[9] Marcos González,et al. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia , 2008, Haematologica.
[10] A. Hart,et al. PRAME expression and clinical outcome of breast cancer , 2008, British Journal of Cancer.
[11] T. Griffith,et al. Role of neutrophils in BCG immunotherapy for bladder cancer. , 2008, Urologic oncology.
[12] K. Odunsi,et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer , 2007, Proceedings of the National Academy of Sciences.
[13] A. Bergeron,et al. MAGE‐A9 mRNA and protein expression in bladder cancer , 2007, International journal of cancer.
[14] V. Reuter,et al. Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma , 2006, Clinical Cancer Research.
[15] A. Sabichi,et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. , 2006, Urology.
[16] M. Pierotti,et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[17] A. Simpson,et al. Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.
[18] Lloyd J. Old,et al. Cancer/testis antigens, gametogenesis and cancer , 2005, Nature Reviews Cancer.
[19] M. Maio,et al. Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2′-deoxycytidine , 2004, Cancer Research.
[20] V. Reuter,et al. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. , 2003, Cancer immunity.
[21] E. Sabo,et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] Yao-Tseng Chen,et al. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. , 2001, Cancer research.
[23] F. Algaba,et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. , 2000, The Journal of urology.
[24] J. Patard,et al. Expression of mage genes in transitional‐cell carcinomas of the urinary bladder , 1995, International journal of cancer.
[25] T. Boon,et al. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[26] P. Bruggen,et al. The CD 4 + T-Cell Response of Melanoma Patients to a MAGE-A 3 Peptide Vaccine Involves Potential Regulatory T Cells , 2009 .
[27] L. Old,et al. Cancer vaccines: an overview. , 2008, Cancer immunity.
[28] Y. Doki,et al. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. , 2007, Cancer immunity.
[29] Y. Horiguchi,et al. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] G. Hermann,et al. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. , 1998, The Journal of urology.